Candriam SCA’s Intersect ENT, Inc XENT Stock Holding History

Candriam SCA’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-554,744	Closed	-$15.5M	–	850
2022 Q1	$15.5M	Buy	554,744 +355,000	+178%	+$9.73M	0.11%	198
2021 Q4	$5.46M	Buy	+199,744	New	+$5.41M	0.03%	351
2020 Q2	–	Sell	-20,000	Closed	-$487K	–	887
2020 Q1	$487K	Hold	20,000	–	–	0.01%	716
2019 Q4	$498K	Sell	20,000 -20,000	-50%	-$405K	0.01%	733
2019 Q3	$680K	Hold	40,000	–	–	0.01%	656
2019 Q2	$906K	Buy	40,000 +10,000	+33%	+$270K	0.01%	668
2019 Q1	$965K	Hold	30,000	–	–	0.01%	641
2018 Q4	$845K	Hold	30,000	–	–	0.01%	616
2018 Q3	$863K	Hold	30,000	–	–	0.01%	649
2018 Q2	$1.12M	Hold	30,000	–	–	0.02%	586
2018 Q1	$1.18M	Sell	30,000 -3,000	-9%	-$110K	0.02%	565
2017 Q4	$1.07M	Buy	+33,000	New	+$990K	0.02%	574
2017 Q3	–	Sell	-35,000	Closed	-$978K	–	756
2017 Q2	$978K	Sell	35,000 -58,000	-62%	-$1.31M	0.02%	580
2017 Q1	$1.59M	Buy	93,000 +12,000	+15%	+$168K	0.03%	484
2016 Q4	$980K	Buy	81,000 +14,000	+21%	+$181K	0.02%	518
2016 Q3	$1.06M	Buy	+67,000	New	+$1.01M	0.03%	486

Candriam SCA's XENT Position: Q2 2022 in Review

Candriam SCA sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 554,744 shares — an estimated $15.5M sold.

Candriam SCA first reported a position in XENT in Q3 2016 and held it in 16 quarters. The position peaked at $15.5M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Candriam SCA reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Candriam SCA sold 554,744 Intersect ENT, Inc shares in Q2 2022, an estimated $15.5M.
Candriam SCA first reported a position in Intersect ENT, Inc in Q3 2016 and held it in 16 quarters.
Candriam SCA's Intersect ENT, Inc position peaked at $15.5M in Q1 2022.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Candriam SCA's 13F filing for Q2 2022, filed 3 Aug 2022.